BOSTON and HONG KONG, Dec. 28, 2023 /PRNewswire/ — Heranova Lifesciences Holding Ltd. (“Heranova”) today announced the successful completion of a USD 13.5 million seed and seed+ financing to develop and offer integrated Women’s Health solutions worldwide. This funding will be used to launch a serial of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programs for endometriosis and bacterial vaginosis. The company is also actively seeking global or regional partnerships for other Women’s Health indications. Institutional investors such as Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital participated in this round.

“Despite the fact that women play a critical role in modern societies and economy, the awareness and solutions for their critical health issues are largely under-recognized and outdated,” said Dr. Jonathan Y. Zhao, co-founder and CEO of Heranova. “As a global Women’s Health company, Heranova was founded with a mission to challenge this status quo by taking a holistic approach so that we could enable women to live their better lives.”

“Endometriosis, for example, is a highly prevalent and debilitating women’s disease with large diagnostic and treatment unmet needs. 176 million endometriosis patients worldwide are suffering from excessive pain, abnormal menstrual bleeding, and infertility,” said Penny Wan, Co-Founder & Chairwoman of Heranova, “Unfortunately, the diagnosis of endometriosis today is often delayed by 8-12 years on average. We will develop innovative solutions to address this care gap.”

“Having access to convenient and reliable diagnostic tests will be a key milestone in the overall management of endometriosis and other women’s diseases,” said Dr. Farideh Bischoff, the Chief Diagnostic Medical Officer at Heranova. “The diagnostic products developed by our R&D team have received endorsement from global leading KOLs as they may help to significantly shorten the time from disease onset to diagnosis and subsequent treatment. To provide an integrated solution, we are also developing first-in-class, non-hormonal therapeutic programs for endometriosis.”

About Heranova Lifesciences

ABOUT HERNAOVA LIFESCIENCES

Heranova Lifesciences is dedicated to developing integrated care solutions for Women’s Health. The company offers internally developed and externally partnered diagnostics, drugs, and devices to address unmet needs in women’s healthcare. Founded in March 2022 by serial entrepreneurs and seasoned executives with support from a world-class Scientific Advisory Board, Heranova has an established global presence with its headquarters in Boston, Massachusetts.

To learn more, visit www.heranova.com.

Cory Dunn, MS, MEd
Heranova Lifesciences Holding Ltd.
+1 760-705-7464
cory.dunn@heranovalifesciences.com
Visit us on social media: